FDA
-
-
-
-
-
-
-
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
-
-
-
-
-
-
-
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
-
-
-
-
-
-
-
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience
-
-
-
-
-
-
-
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance
-
-
-
-
-
327,292 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

